{"schema_version":"secwatch.filing_event.v1","accession":"0001437402-25-000008","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.412117+00:00","generated_at":"2026-05-17T03:52:14.065039+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ardelyx appoints Sue Hohenleitner as CFO","bullets":["Appointed Sue Hohenleitner as CFO effective Nov 4, 2025; she joins Oct 13, 2025.","Hohenleitner previously VP & CFO of J&J Innovative Medicine NA ($36B business).","Annual base salary $550,000, target bonus 45% of base, sign-on bonus $180,000.","Received option to purchase 578,104 shares at $5.01/share and 146,896 RSUs, four-year vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001437402-25-000008","json":"https://secwatch.observer/filing/0001437402-25-000008.json","markdown":"https://secwatch.observer/filing/0001437402-25-000008.md","text":"https://secwatch.observer/filing/0001437402-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000143740225000008/0001437402-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000143740225000008/ardx-20251013.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:52:14.065039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}